šŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Zymeworks Inc. (ZYME)
NASDAQ: ZYME Ā· Real-Time Price Ā· USD
26.04
+0.20 (0.77%)
At close: Nov 18, 2026, 4:00 PM EST
26.24
+0.20 (0.77%)
After-hours: Nov 18, 2026, 5:49 PM EST
← View all transcripts

Stifel 2026 Healthcare Conference 2026

Nov 11, 2026

Summary

Zanidatamab’s potential $500M–$900M in royalty income supports a flexible model combining R&D, buybacks and opportunistic M&A. Pipeline priorities include partnering ZW191, advancing differentiated programs and exploring investor-backed spinouts for pan-RAS ADCs.

Steve Willey
Analyst, Stifel

All right, we're going to go ahead and get started. Thanks to everyone who's stuck around for the last presentation of the day. I am Steve Willey, one of the Senior Biotech Analysts at Stifel, and glad to have with us here to wrap things up Ken Galbraith, who's the CEO of Zymeworks. Ken, any opening statements you want to make before we I know it's been an incredibly busy year for you and your team, and I'm sure seeing Zani getting across the finish line in frontline GEA had to have been the highlight.

Ken Galbraith
CEO, Zymeworks

Yeah, there's nothing better than working in this business and realizing you've done something that changes the standard of care for a big patient population. By changing, I mean you give a median OS benefit for patients with GEA in the HER2-expressing space, it's eight months by this timeframe, and that's on the median. You realize in some part of the patient population, you're giving them a long-term durable survival benefit. I mean, that's why we do this—

Steve Willey
Analyst, Stifel

Yeah.

Ken Galbraith
CEO, Zymeworks

—this work. That's really gratifying for us to realize that's something we invented, came up with. It's pretty unique and differentiated. No one else is really doing the same thing, which is the heart of our business to find that. We found a way to develop that in the clinic. We found a way to bring on BeOne as a partner in Asia Pacific, and having the ability to do clinical studies in that indication, specifically in China and rest of Asia, was so important. We wouldn't have got it approved without that.

Then bringing on Jazz as a partner in 2022 to provide the additional resources to get us across the finish line and launch, as they're doing now in the U.S. I mean, all of that was a long 10-year timeframe, and a lot of times in biotech, it doesn't end in that type of positive outcomes. We're pretty encouraged by that, and it makes you want to do it again.

Steve Willey
Analyst, Stifel

Yeah.

Ken Galbraith
CEO, Zymeworks

I think we're focused. We celebrated, I think, that day for patients. The next day, we said, "Look, how do we get this feeling again with the innovative R&D we have?" And we have to find a way to turn that into a new medicine somehow to help patients and keep a share of that success for our shareholders to reward them for the risk capital that's put up to make those innovations. Pretty excited.

Obviously, at the beginning of the year, we set a pretty aggressive agenda for moving every part of the business in this diversified business model that we have, to showing how improving all the different components that we have available to us can end up in something that's much more valuable at the end of the year. As you saw in our Q3 earnings on Monday, we've done a lot of it.

Steve Willey
Analyst, Stifel

Yeah.

Ken Galbraith
CEO, Zymeworks

There's still seven weeks left in the year, so there's still time to do the rest of it. But I think hopefully by the end of the year, and we're sitting early in January, we can talk about all the work we did to move different parts of the business together, which cumulatively together really showed a huge appreciation in value for our shareholders and moved a lot of new medicines closer to where zanidatamab is.

Then for 2027 and 2028, we just need to do it all again, do it better, faster, bigger outcomes for us in terms of value, and find the next zanidatamab somewhere in that portfolio that we can work upon. Pretty excited where we are for this year, but looking forward to where we need to get to over the next two years to really show how this diversified business model can be effective in turning R&D innovation into something that's meaningful for patients and shareholders at the same time.

Steve Willey
Analyst, Stifel

Okay. Yeah, I know the visibility you've been able to gain into Zani with respect to milestones and royalties has really allowed you to kind of lean into this thing now, right? I know it is a little bit non-traditional. I know it is a fairly simplistic concept, right? You are going to preserve long-duration cash flows and still do R&D, right? It seems pretty simple. But I know it is kind of against the traditional biotech dogma. As you have been out, like post-leaning into this, pretty aggressively, how has that messaging process gone with investors?

Ken Galbraith
CEO, Zymeworks

Yeah, it might be a different pathway than people are used to think about how do you take an R&D innovation and turn that into something valuable for patients and shareholders? We just think there is multiple ways to do that. We made the choice with zanidatamab not to forward integrate to our own sales force, at least in the U.S., to drive that. We felt partnering that would be a better solution for our shareholders in terms of the risk-return profile. We certainly avoided a lot of dilution of capital to get Zani to this position.

The share of success we will get from Jazz and BeOne on Zani is pretty fundamental to our shareholders, and pretty interesting from that construct. I think once you have made that decision, it does open up lots of optionality and flexibility on how do we move interesting R&D forward, that is just not off our balance sheet, unencumbered, hoping we can take it all the way ourselves. I think we have seen lots of situations where that works out, and we have seen lots of situations, probably more, where that does not, or the equity dilution and the risk associated with that, the binary risk associated with some of those studies destroys shareholder value.

At this point, we think we have a really good, interesting shareable model based on just our existing partnered programs. If you look at just zanidatamab over its lifetime, hopefully pasritamig has a successful phase III readout in the first prostate cancer phase III next year. That is also an interesting component for us. We have a commercial product, YUPELRI, that we acquired in the Theravance acquisition that we co-promote with Viatris, which can also add to the top line. We have a really great shareholder model with what we have right now, and what we are trying to do is be additive to that without destroying that value that is in front of us.

I think when you look at the way that we construct capital planning and development plans and partnering strategies around future R&D innovations, you will start to see that we have more optionality than just leaning into our own balance sheet and using that to develop things on our own. We did a recent Roche deal, which I think is interesting. We have talked about the fact we are still working on the idea of carving out or spinning out a portion of our portfolio around the pan-RAS ADCs, which gives us an equity stake and a royalty stake in something, but relies upon investor capital to fund something forward from where we have gotten this right now.

I think there are other elements we can still execute to show how we do that. At the same time, we are still at the heart of innovative R&D companies. I think if you look at our recent scientific disclosures, at SITC last weekend, we put it up pretty innovative trispecific PD1 VEGF IL-7. We are already trying to move the needle on PD1 VEGF, and that is a really interesting trispecific, and I do not think anyone else is doing that. We are showing the innovativeness we have.

If you look at upcoming at ASH, we have an abstract that we will present around a penta-specific antibody. We move rapidly from bispecifics to trispecific engineering to now, five arms of an antibody that can be useful in a single biologic for AML. It is logic gated, it is really interesting, it involves our Co-Stim platform, and no one else is really doing that. That really will be the first scientific disclosure of a real penta-specific antibody. It shows our protein engineering skills, shows our innovation.

What happens after that, how we develop those, and whether we do those ourselves on our own balance sheet for a while, partner those, think about those as a future spinoff. We have lots of optionality to consider how we do that and how we allocate capital to those things. I think you can still be an innovative R&D company, you can still develop a financial construct which provides your shareholders with the right risk-return relationship around innovative R&D, and you can do it in a way that does not destroy the value we have built up so far, but can be additive to that value in years to come.

Steve Willey
Analyst, Stifel

How do you now think about, and again, maybe this is a more relevant question with Jazz increasing their peak sales guidance to $3 billion-$5 billion, but there is obviously a near-term path, if not a media path, to sustainable profitability. How do you think about allocation of capital now, right, between the kind of three different pillars, whether it is internal R&D investment, whether it is strategic acquisitions, whether it is share repurchases? Are these just cut-and-dry, cost-to-capital-driven decisions, or are there some other kind of guiding set of principles that you are leaning on as you think about how to allocate across the business?

Ken Galbraith
CEO, Zymeworks

Yeah, I think we look at all that through a strategic lens. And obviously, Jazz's peak sales guidance that they have set out now of $3 billion-$5 billion peak sales opportunity for Zani. I think back in 2022 when we did the partnership with Jazz, we always thought it could be a $1 billion-$5 billion peak sales asset. I know that is a broad range. Now it is narrowed to the high side, which is great. And what we start to think about is that peak sales, that means between $500 million and $900 million in royalty income for us. So, don't have that all today, but we need to think about how we allocate that capital thoughtfully into the right places now, because that is only going to become a continued issue for us.

I think if you look at what we have done this year, that is a pretty good illustration of the way we think about it. So, one, we have a kind of a core R&D funding in our organization. And yes, it is about 20% less than it was last year. But it is still a pretty substantial commitment to a pretty broad class of molecules and therapeutic categories, and that will always be in there as a core. And I think it is still meaningful. If you look at our Q3 results, you will see that. At the same time, we borrowed some money from Royalty Pharma against the future Zani royalties of $250 million. We put half of that into a stock buyback, and we used the other half of that to make the Theravance acquisition.

And beyond that, we supplemented the share buyback with some additional proceeds. So I think we are over $150 million in buying back shares this year. In total, I think we have bought back 14 million shares since we started doing this. So we have bought back almost 20% of the company o ver the past two years at a price that we think is attractive to shareholders because we think the underlying value is still much higher. I think you can see how we can have the right mix of a core R&D funding, a core commitment to always returning capital to shareholders on a regular basis, and a commitment to being opportunistic on M&A when it presents itself. It is about getting the balance of those three things right.

At the same time, if we are able to run our business properly with the right financial discipline, we will have excess cash flow every year. I mean, we have it now. Then we need to think about how do we supplement those core positions and which ones do we supplement, and that will be opportunistic. There is no formula. If we see an additional great R&D opportunity, maybe we take the upfront from Roche that we receive in December, $55 million, recycle that back in R&D to actually do something more there. If we see an opportunity to maybe buy back more shares than we contemplate now, we can be more aggressive there. If we see an M&A opportunity, we can save some firepower to fund that.

It will be strictly opportunistic. It is about getting the right balance between all three of those elements. If we get that right balance, then on a longer-term basis, we think driving total shareholder return over the long term will be pretty interesting in that model. If we can continue to execute in 2027 and 2028 beyond the way we did this year, then I think that is a really interesting construct, and there are still opportunistic ways for us to rebalance that by leaning into one or the other over time, and that is the way we will think about it.

For next year, there is no predetermined allocation of all the excess cash flow we think we have. We will have some available that we can put to work when we see the opportunities. But we will always support R&D. I think returning capital to shareholders is a good thing for biotechs to do, and we think there are more M&A opportunities for us to be opportunistic about beyond Theravance.

Steve Willey
Analyst, Stifel

Okay. Yeah, I think the Theravance was, or that acquisition was interesting, right? Because I know that you had been kind of messaging the strategy here, right, is like you are able to look at things, whether they are assets or opportunities, that maybe some of the—

Ken Galbraith
CEO, Zymeworks

Yeah.

Steve Willey
Analyst, Stifel

—traditional acquirers in the space wouldn't be willing to do. Do you kind of feel like having that perspective on the business development landscape, having that kind of flexibility gives you kind of a little bit of a monopoly in the corner of the market where you can do things in a way that aren't necessarily your traditional bidding war processes that tend to play out?

Ken Galbraith
CEO, Zymeworks

Yeah. Usually we don't like using the word monopoly in our business unless I'm playing a board game with my children. But when I think about putting yourself in a position where no one else is, and we like that. On the R&D side, we do that. Think about zanidatamab, that's a unique differentiated molecule, and nobody's been able to really repeat our protein engineering success with Zani. That's clear.

I think if you look at pasritamig, which we built with J&J around their KLK2 antibody, that's a unique structure, I think, for sure. I think if you look at ZW209 that we just partnered with Roche, that's a really specific structure. This Co-Stim platform is very unique and differentiated to us. If you look at our two most recent scientific disclosures that we've made or making, we're doing things that no one else is really trying to do.

For the R&D perspective, we always try and put ourselves in a position where we're unique and differentiated and think there's a lot of value and benefit from that. There's no reason we can't have that same approach on the acquisitive side of the business. So, being interested or ascribing value in things that maybe others can't find a way to ascribe value is the way I think that you find mispriced opportunities in M&A.

I think we're really excited about the Theravance opportunity. I think we paid a fair price, but not beyond a fair price. I think we were one of the few people that were in that bidding process, if you look at the merger summary, that were able to ascribe the right type of value to convince Theravance's shareholders that that was an interesting proposition for them.

Our entire IRR is based upon modest growth in YUPELRI and the financial structures that we use underneath that with the cost of capital to acquire that. That drives the mid-teens IRR. Everything over that is upside. YUPELRI growing beyond people's expectations, making utilization out of the R&D assets, which has been in Theravance for 30 years now of their 30-year life. Some of the other licenses, the tax attributes, that's all upside.

I am very pleased we were able to find an opportunity like that where we were probably the folks who could ascribe the most value and be the obvious acquirer, but not overpay, not lean in too far on what has to happen for that IRR to be achieved, but be able to use the upside in R&D and tax attributes in a way that others couldn't. That's not the only one. That was the one that was transactable for us and we wanted to do first.

I think there is a number of other situations where we might be the most identifiable acquirer who can ascribe the right value to the counterparty, but not have to lean in so far that we have to stretch ourselves to be able to make that IRR, that target IRR happen. I think we are obviously still looking at other opportunities where that makes sense for us in the business.

Some might lean more into the commercial side of the business as Theravance did, because YUPELRI was the reason to do that for the IRRs. That's a commercial product in the U.S. that we have a co-promote right with Viatris with. Some of those things might lean more into R&D assets, which we think are really interesting additions to our own R&D portfolio, and some might be a different balance than maybe you saw in Theravance.

That being said, we would love to find ourselves alone in the R&D business and working on something. That's what we all try to do. It's just really hard. I think we would love to find ourselves alone on an M&A transaction that makes the most sense for us and no one else. I think we will always do well if we can find ourselves in those situations with both R&D and M&A strategies.

Steve Willey
Analyst, Stifel

Okay. Maybe we can talk about the pipeline.

Ken Galbraith
CEO, Zymeworks

Sure.

Steve Willey
Analyst, Stifel

Start with a place where you're not alone, which is ZW191. We saw the data at ESMO.

Ken Galbraith
CEO, Zymeworks

Yeah.

Steve Willey
Analyst, Stifel

I still think that there's some clear differentiation here.

We haven't seen with some of the other folate receptor alphas. We know that there's a lot of them. I think you're kind of running a process now to find a strategic partner. Just curious, based upon kind of the updates that we've seen for that asset over the, at ESMO and prior to, where do you see opportunities for differentiation, just kind of relative to the data you've presented to date?

Ken Galbraith
CEO, Zymeworks

Yeah, I think we had a really interesting idea back in 2023 with the approval of mirvetuximab, is that we could do better with a topo-loaded ADC. We set out ourselves the idea that we could create molecules that would be superior to that. We created ZW191, which is our folate receptor alpha targeting ADC with our own payload on it. We also developed ZW220, which was our NaPi2b-targeted program. Also for gynecological tumors with our topo payload. We felt we could beat mirvetuximab. That would just be an improvement for patients, and we should pursue that. That would be both beating it in the label indication for mirvetuximab, but also broadening out the usage.

If you look at our data, our data supports exactly what we designed. I think we see clear differentiation in the mirvetuximab label, where I think we've been able to generate from a 40% ORR, at least in our data set, above 70%. So a pretty substantial difference in ORR for that patient population on label, which has translated into some interesting duration of those responses. We have the ability to broaden out the label beyond that. I think there's some clear differentiators in the way that we look at our ADC. We do see some relationship between the response rates and the expression profile of folate receptor alpha. That's where we think ADCs work best.

I think what's happened in ADC development in gynecological tumors is that we've seen a flood of folks with different targets, different payloads, different linker strategies, pursuing unselected patient populations, trying to cover the entire segment of patients with gynecological tumors, whether it's PROC or PSOC. That's just created a competitive environment that really is a little beyond what we expected. Clearly, we still see differentiators in our molecule. I think ZW191 is pretty interesting for further development. It just makes it harder for us to commit our shareholder capital to continue to pursue that on our own.

I think we made the decision, and we've talked about this earlier this year, that we think that's a really interesting asset. We think it does deserve further development. It is something that could provide a differentiated clinical benefit if it's moved to market. We just have to find somebody who understands that and is willing to push that forward. We were in a very similar situation with Zani back in 2021, where I think people didn't think it was competitive within HER2. There were all sorts of other ADCs being competitive, and it was Jazz who shared the belief with us that this could be a really successful product and new medicine in the HER2 space and joined us.

I think we just need to find that same person with that same belief who wants to put their capital, their resources alongside us to move that forward. I think it is really interesting. The other ADC we developed that same time was obviously ZW251 on the GPC3 for HCC. Not as many ADCs have been developed there. We are seeing obviously some of the bispecifics be there, but that is one that I think we have the same idea that we can really move the needle in a first-line situation with people with HCC, really as a combination therapy with immunotherapy, which is used now as a standard of care. That one is not as competitive r ight now. Hopefully it stays that way because we have got a really good molecule.

I think it just tells you like to be in positions where you can be by yourself and more unique and differentiated and own a category. Sometimes you will start out with that idea. If a part of that changes for you, then you do have to react to that. I think specifically in gynecologic tumors, we did not take ZW220 into the clinic. We stopped it right at IND. It is a really interesting molecule as well, the NaPi2b targeted. The folate receptor alpha targeting, we have invested clinical money and still are, but the idea of going alone without a partner just seems like it is not the right competitive move to make.

We have been focused on finding a partner to provide the resources to move that forward. GPC3 still has a pretty good feel about being unique and differentiated in the ADC format. Obviously, we have got to follow the activity and tolerability around the 4-1BB bispecifics, which look interesting as well. But that is one I think just still supports a really interesting prospect that it is as unique and differentiated as we set out when we started that program.

Steve Willey
Analyst, Stifel

So maybe with respect to ZW251, and maybe this is a question that applies to the rest of the pipeline, but how do you broadly think about kind of striking a balance with respect to the amount of clinical data that you need to generate for an asset when you ultimately want to find a partner for it, right? So in the case of ZW251, you are running the dose escalation, presumably dose expansion single agent now. Would you kind of feel like you would need to run a cohort of frontline patients in combination with IO to kind of establish that combinability profile in frontline patients before you could give that to a strategic?

Just curious as your thoughts as you look now to partner more things, right? I think like valuations for a lot of these early-stage assets seem pretty healthy right now, right? I'm guessing there's a point whereby generating more clinical data doesn't necessarily get you paid more. Is that the right way?

Ken Galbraith
CEO, Zymeworks

I think that's right. There's two things really. We don't have any predefined notion of how far we take something in development. Every stage of development has to be justified by data. I think that's an important point for us to have internally at least. There's no predefined point. I think if you look at ZW209, it is a good example. We're ready to put that in the clinic ourselves, and we had a potential partner who became our partner, Roche, who had a desire to get involved with that earlier than clinical data so they could help to help manage the clinical development program from the start.

We thought that was a pretty reasonable proposition that as long as we got the right financial structure, that made a lot of sense to us. Made a lot of sense to us in terms of just being able to move that forward maybe faster or more broadly than we could do on our own with more capital. Also, we could certainly see small cell lung cancer turning into more of a combination therapy approach than maybe we thought a couple years ago when we started working ZW209.

You've seen the benefit of a T-cell engager with PD1 now from ESMO. You're still seeing more and more interest in maybe combining a T-cell engager with an ADC, whether it's the same TA or a different one for small cell lung cancer. You might find the actual real solution for patients is thinking about a combination of a T-cell engager, immunotherapy, and an ADC, if it can be tolerable. I think when those combination approaches come up, it just leads you to think about, can I find a partner now that has all of those elements and removes this idea about then how do you do combination regimens later by trying to get access through clinical collaboration?

I think Roche was a natural for us because they have a PD1, they have immunotherapy, they have ADCs that might read on small cell lung cancer. That drove that one by interest and wh at the entry point would be. I don't think we're all tied to that. I think our R&D portfolio is always going to be a combination of three things. I think things that we keep unencumbered that we're driving with our own shareholder capital, and we can take that into the clinic and develop clinical data with that if we want. We're going to have a part where maybe we make a decision about partnering strategically, and that's ZW209.

That brings us financing resources maybe we don't have, plus it monetizes some capital we can redeploy elsewhere. I think the third leg, which we're still waiting to execute on, which hopefully we'll show soon, is this idea that maybe we think about partnering with financial investors to put something in a dedicated spinoff entity that then can be pushed forward where I don't own 100% of it, but I own a big stake of the equity and I have a license on a royalty. So I get both of those, and that's my return. I think we can see our portfolio developing over time to having all three of those elements.

We'll always have unencumbered R&D that we're investing our own shareholder capital in for upside, and we'll always have partner programs where it makes more sense to work with someone else and their capital. I think we've got this third area that we're trying to show we can do, which will be partnering with financial investors to move things forward, where I have an upside in the equity stake I own and plus a royalty interest in that portfolio. So I think that's how we'll try to develop it. Those things are stage agnostic. So I don't think we're as concerned about the stage and predetermining it.

Just looking at interest, looking at strategic reasons why partnerships might make sense. That's probably ZW191, that's probably much more interesting for us to think about a partnership because of the competitive nature, and with ZW251, it's less of a concern right now. And I think in ZW251, if you think about combination therapy, getting access to a PD1 and Bev is a little bit easier to think about than getting access to another element that might be necessary as we are in small cell lung cancer with Roche.

Steve Willey
Analyst, Stifel

Okay. So with respect to this notion of maybe trying to pursue spin-outs and sourcing external investor capital, it sounds like that can occur in a way that is stage agnostic, right? So, I know you have referenced the pan-RAS payload, the ADC platform that you have as maybe being kind of a poster child for that opportunity. I do not know if you have declared development candidates or not, but it sounds like in a stage agnostic way, maybe you do not in order to create that structure.

Ken Galbraith
CEO, Zymeworks

Yeah, I mean, if you look at our pan-RAS ADC portfolio as it sits right now, there are four development candidates in there. Three we publicly disclosed at AACR, one we haven't talked about publicly. I think partnering one of those is not the best way to get value out of that. I think being able to move all of that forward in an unencumbered way would be the best value proposition, but that requires more capital than we can provide for that, to do that on a timely basis.

I think finding a way to partner with investors, which then keeps those programs unencumbered for us and those investors, is probably the right thing to do right now. Then move those into the clinic as quickly as we can, and let clinical data decide which of those might be more interesting beyond that. I think that's a really interesting construct for us strategically, is to keep those unpartnered specifically, but not have the drag of funding all of those on our balance sheet or off our P&L. We can bring in financial partners to help do that and keep a good stake and keep a royalty interest, and just let those, see what happens with those.

We're really interested in how that works, and pan-RAS just popped up as something that seemed like it was a whole new company within Zymeworks that was created, and we're not in the business of trying to fund multiple companies. We're trying to fund one good one. I think it's also an illustration of just how productive and diverse our R&D group is, and they keep generating these opportunities which are just unique and differentiated, but require capital to move forward, and we have to find a way to do that just doesn't do it all off our P&L or off our balance sheet.

We have a great financial foundation, but it doesn't mean that's the obvious place, the default that that's where it has to go. Using these partnerships like we did with ZW209, using a spin-off, which we hope we can do for the pan-RAS ADCs, that just gives us a thought about this unencumbered piece that we do on our own, can be a part of the R&D portfolio, but not all of it.

Until our R&D group stops being productive and creating all these great things inside the company, we'll have to keep using that model. So far from what we see, and I think our recent two scientific disclosures around the PD1 VEGF IL-7 and around this penta-specific antibody in hem-onc, which is our first hem-onc disclosure, you just don't see the end to how productive that group can be.

We won't constrain them with our balance sheet. We will find ways where we can use partners and investor capital to make sure that all the ideas that we think deserve to be moved forward, we can move forward. That will build a lot more value for our own shareholders than trying to be capital constrained and not pursuing those opportunities in the way that I just described.

Steve Willey
Analyst, Stifel

Would you want to maintain a majority ownership stake in these spin-outs, or are you agnostic to that?

Ken Galbraith
CEO, Zymeworks

I think we want to make sure we have the right share of success, given the fact that investors we bring in share risk with us. Bringing Roche into ZW209, they are sharing risk with us. From day one, they are sharing clinical risk. I think we just want to make sure that we have our proportionate share of success, and also if there is upside, that we can get that.

I think in the zanidatamab deal with Jazz, we did a good job of making sure that if there was more upside than we thought there would be in zanidatamab, which there is, we are making sure that we have our share of success of that and not be monetized and topped out in how we share that. We are more interested in maybe the structure of that and just make sure that we are treated fairly along with others who are joining us to share risk and share capital.

Steve Willey
Analyst, Stifel

Okay. I thought the timing of the DLL3 transaction with Roche was pretty interesting, right? I mean, it was, I think, on the day or before the day we saw the tarlatamab data at ESMO, right? I think it was certainly a signal from Roche that there's more differentiation to do in this space, right? The game is not over.

Ken Galbraith
CEO, Zymeworks

Yeah, sometimes timing just works out the way it works out.

Steve Willey
Analyst, Stifel

Yeah.

Ken Galbraith
CEO, Zymeworks

But certainly, we were ready to move that molecule in the clinic ourselves. We love our Co-STIM platform. We got a lot of TriTCEs that we have in the portfolio that are preclinical, but bringing them along from day one, going in the clinic, just made a lot of strategic sense for us, and the structure of the deal just allowed us to think that's a pretty fair proposition for someone who's going to come in and share their capital and risk at that stage. And the validation they can provide in ZW209 will just open up a whole platform of other TriTCEs with the same Co-STIM technology platform in it that are all still owned by us.

Steve Willey
Analyst, Stifel

Do you think that TriTCE platform, and again, I think that was maybe the first glimpse of all those preclinical candidates that you have in development. That is the first time that we had seen it.

Ken Galbraith
CEO, Zymeworks

Yeah.

Steve Willey
Analyst, Stifel

I would imagine, or maybe I would speculate that that tech platform would also perhaps be ripe for a spin-out candidate as well. Is that a fair assumption, or do you think you are better off maybe doing those on a one-off basis?

Ken Galbraith
CEO, Zymeworks

Yeah, I think we have the option to make decisions about what we keep as unencumbered, we want to do ourselves, what we might partner. And what we might think might make sense to go into a spin-off with financial investors as partners, as opposed to a pharma company. We do not try not to predetermine that. We try to look at all of those options and think about what is the best thing for the product. And if you do that, it usually ends up being the best thing for the company and our shareholders. We are pretty excited about the prospect of doing that.

No one has figured out the Co-Stim platform in a single trispecific. Certainly, J&J showed at SITC, with their combination of a CD3 bispecific, pasritamig, and the CD28, as well with the PSMA, that two signals together can be more interesting than one single when you are talking about T-cell engagers. I think they certainly showed that, and what we're going to try to show with DLL3 and the other ones is that having that controlled within a single biologic structure might even provide more advantages than two bispecifics given separately. That data was pretty validating for this idea that a little bit of a push with a second signal through CD28 can really enhance what already was a really great bispecific antibody in pasritamig.

That data was pretty encouraging for us. If we get that right in a single biologic structure, which we can show with ZW209, then I think that is a winning platform, and we have a lot more we can prosecute beyond that, whether we do it ourselves, do some more with partners on a one-off, or think that maybe goes into something that could be a broader spin-out with investor as partners. We can make that decision once we're there.

Steve Willey
Analyst, Stifel

Okay. Anything we didn't cover you want to just quickly mention before we wrap up?

Ken Galbraith
CEO, Zymeworks

I think we're. Hopefully, you can see we think this diversified model of all these different attributes adding together is the way to build value, at least for us and where we're situated. It's important that we have multiple ways of building value and multiple approaches and thoughtful capital allocation to drive that. I think hopefully this year we started to illustrate how we think that makes sense and works, and you can hopefully see that in our Q3 earnings based on the progress we were able to make for the first nine months of the year. We just have to stay diligent and just repeat that over and over again and get better and better at this. I think if we do that, we'll build a lot of long-term value for our shareholders.

Steve Willey
Analyst, Stifel

All right. Ken, thanks a lot.

Ken Galbraith
CEO, Zymeworks

Thank you . Appreciate it.

Steve Willey
Analyst, Stifel

Thanks, everyone.